Over 20 Qiming Venture Partners Portfolio Companies Win 30 Awards in Qingke’s 2025 VENTURE50 Ranking

Recently,The results of the 2025 VENTURE50, initiated by Zero2IPO Group and Investment界, have finally been unveiled.This selection continues with the风云50 (Fengyun 50) and 新芽50 (New Bud 50), as well as the three major industries of artificial intelligence, hard technology, and life science. Among them, the 风云50 (Fengyun 50) companies are unlisted enterprises that are in the financing stage after Series B or established before 2022, while the 新芽50 (New Bud 50) companies are unlisted enterprises in the financing stage of Series B or earlier and established after 2022. The 人工智能50 (Artificial Intelligence 50), 硬科技50 (Hard Technology 50), and 生命科技50 (Life Science 50) represent high-growth companies with outstanding performance in these industries by 2025.

Qiming Venture Capital's portfolio companies—Galaxy General Robotics, Zhipu, Mech-Mind Robotics, Minghui Medical, Conorth, Wushuang Medical, Insilico Medicine, Tashi Intelligent Aviation, Wuxun CoreSky, Zean Biotherapeutics, AIXIN Intelligence, Homomorphic Intelligence, Mifan Technology, Biren Technology, Zenitar, TingSheng Technology, Shize Biotech, Wushuang Medical, Tianchen Biotech, Tupai Medical, Xiyuan Anjian, Yijie Lituo—won 30 awards.

Galaxy General Robot, Zhipu, Mech-Mind Robotics
Minghui Medical, ConnoSense
Unique Medical, Insilico Intelligence

Selected

2025 Venture50 Enterprise Rankings

It Stone Intelligent Navigation, No Question Core Horizon, Zenitar Biomedical

Selected

2025 Venture50 Emerging Enterprises List

Galactic General Robotics, Zhipu
Mech-Mind Robotics, Itshi Zhihang

SELECTED

Venture50 of Artificial Intelligence in Investment Field 2025

AIXIN Yuanzhi, HOU MO Intelligence, MI FEI Technology, BI REN Technology

Selected

Venture50 of Hard Technology in Investment Field 2025

Zenitar, TingSheng Technology, MingHui Pharmaceuticals
Connorset, Zenitar Biopharmaceuticals, Shize Bio
Wushuang Medical, Tianchen Bio, Tupai Medical
Xiyuan Anjian, Yijie Litech, Insilico Medicine

SELECTED

Venture50 in Life Science & Technology Investment Field 2025

VENTURE50 has undergone two decades of development and refinement, and has now become a benchmark for investment in high-growth enterprises in China.The 2025 selection, through multiple rounds of online evaluations and offline matchmaking, has created an efficient interactive platform for technology innovation enterprises and investment institutions. It actively promotes the integration of industry and capital, discovering and witnessing countless outstanding technology innovation enterprises grow from "new shoots" into "unicorns." This fosters the deep integration of industry and capital, serving the high-quality development of China's technology innovation industry.

Among the companies selected for the 2025 VENTURE50 Top 50 and Rising 50 lists, artificial intelligence (AI) firms dominate, accounting for 49%. Embodied intelligence, generative AI, and "AI + vertical scenarios" have become focal points for venture capital investment, driving AI's gradual shift from technical concept validation to commercial implementation. With policy support and market demand creating a triple-driver of "technology-capital-scenarios," the AI industry is transitioning from the "model explosion phase" to the "scenario realization phase," injecting strong momentum into high-quality development.